Long-Lasting Antiandrogen Withdrawal Syndrome in Castration-Resistant Prostate Cancer: Three Cases With Complete Response
The Korean Journal of Urological Oncology. 2018;16(1):38-41 
Durable Complete Remission From Castration-Resistant Prostate Cancer With Sipuleucel-T After Estrogen Withdrawal
Clinical Genitourinary Cancer. 2014;12(2):e55-e58
Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer
Clinical Genitourinary Cancer. 2018;16(1):e169-e172
Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: Two case reports
International Journal of Urology. 2006;13(9):1259-1261
Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: A single-center experience
International Journal of Urology. 2010;17(11):950-955
The Antiandrogen Withdrawal
Syndrome in Relapsed Prostate
Cancer
European Urology. 1997;31(2):3-7
An enzalutamide antiandrogen withdrawal syndrome
Nature Reviews Urology. 2014;11(7):366-366
Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate
Urology. 1995;45(4):700-705
Castration Resistant Prostate Cancer: Role of Chemotherapy
Prostate Cancer. 2016;509-514
Adaptation and clonal selection models of castration-resistant prostate cancer: Current perspective
International Journal of Urology. 2012;20(4):362-371